Diabetic Neuropathic Pain, Healthy Volunteers, Renal Impairment
Conditions
Brief summary
Researchers are looking for a better way to treat people who have inflammatory conditions. Inflammatory conditions may result from an increased activation of the body's natural defenses (the immune system) and are characterized by swelling, redness, heat, and pain. The study treatment BAY2395840 is under development for use in inflammatory conditions. It works by blocking a protein, the B1 receptor, whose activation is involved in inflammatory responses. The main purpose of this study is to learn how a single dose of BAY2395840 moves into, through and out of the body in participants with a moderate reduction of kidney function compared to matched participants with normal kidney function. To answer this, the researchers will compare: * the (average) total level of BAY2395840 in the blood (also known as AUC), and * the (average) highest level of BAY2395840 in the blood (also known as Cmax) between the two groups of participants. The participants do not benefit from this study. However, the study will provide information on how to use BAY2395840 in later studies in people with inflammatory conditions. As some people with these conditions may also have kidney problems, this study is done in participants with moderate reduction of kidney function to characterize the use of BAY2395840 in this patient group. All participants will take a single dose of BAY2395840 as tablets. Each participant will be in the study for up to 5 weeks. They will stay in-house for 4 days, including one treatment day. In addition, one visit before and one visit after the in-house phase to the study site is planned.
Interventions
DRUGBAY2395840
Immediate release (IR) tablet, oral administration
Sponsors
Bayer
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Participants must be 18 years of age or older, at the time of signing the informed consent. * Participants who are - apart from renal function - overtly healthy for their age as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. * Participants with moderate renal impairment with an eGFR of 30 to 59 mL/min/1.73 m\^2 (inclusive) according to the Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI) * Normal renal function, as assessed by estimated glomerular filtration rate (eGFR) based on serum creatinine at screening according to the modified Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI) formula: eGFR ≥90 mL/min/1.73 m\^2. For participants with an age of 65 years and older, an eGFR of ≥ 60 mL/min/1.73 m\^2 is acceptable. * Body mass index (BMI) within the range 18 - 32 kg/m\^2 (inclusive). * Male and female participants had to use safe contraception, as defined by guidelines for contraception in clinical studies. * Capable of giving signed informed consent.
Exclusion criteria
* Medical disorder, condition or history of such that would impair the participant's ability to take part in or complete this study. * Acute renal failure or acute nephritis within the past 2 years. * Existing chronic diseases requiring medication (applicable only for Group 2 and Group 3 for those younger than 65 years).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Area under the concentration vs. time curve from zero to infinity (AUC) after single dose of BAY 2395840 | From pre-dose up to 72 hours post administration | AUC(0-tlast) will be used as the main parameter if AUC cannot be reliably determined |
| Maximum observed drug concentration in measured matrix (Cmax) after single dose of BAY 2395840 | From pre-dose up to 72 hours post administration | — |
| Unbound area under the concentration vs. time curve from zero to infinity (AUCu) after single (first) dose of BAY 2395840 | From pre-dose up to 72 hours post administration | AUC(0-tlast)u will be used as the main parameter if AUC cannot be reliably determined |
| Unbound maximum observed drug concentration in measured matrix (Cmax,u) after single dose of BAY 2395840 | From pre-dose up to 72 hours post administration | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with treatment-emergent adverse events (TEAEs) | From application of study intervention until follow-up Day 9 |
Outcome results
None listed